This is a type of transplant where the donor and recipient are genetically identical. Think of it like a twin transplant! It's used when the donor and recipient are the same species and have the same genes, like identical twins or members of the same animal breed. This makes it easier because the body won't reject the new tissue or organ.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
An isograft is a transplant in which the donor is the recipient's identical twin. Identical twins share the same genes, so the donated organ or cells carry the same tissue markers as the recipient's own body. Those markers are what the immune system uses to tell its own tissue from something foreign, which is why an isograft avoids the mismatch that drives rejection in other transplants. The term is also used in laboratory research for grafts between animals of the same inbred strain. In people, isografts fall into two groups. The first is a living-donor organ transplant, most often a kidney and less often part of a liver, a segment of small intestine or part of a pancreas. The second is a blood stem cell transplant (often called a bone marrow transplant), known in this setting as a syngeneic transplant. It is used for blood cancers such as leukemia, lymphoma and multiple myeloma, and for bone marrow failure such as aplastic anemia. Fraternal twins and other brothers and sisters are not genetically identical, so a transplant from them is a standard donor transplant, not an isograft. Few people have an identical twin who can donate, so most of what is known comes from transplant registries, small case series and individual reports rather than clinical trials.
The first step is confirming that the twins really are identical. Transplant centers usually do this with DNA testing rather than relying on appearance or birth records, because the whole plan depends on the match. Both twins are then evaluated. The recipient has the usual assessments for the organ or stem cell transplant they need. The donor twin is checked to make sure donating is safe for them and that the organ or cells are healthy. Because twins share their genes, the team also considers whether an inherited condition that harmed the recipient could affect the donor or the donated organ. For an organ transplant, preparation looks much like any living-donor transplant: blood tests, imaging, a review of medicines and planning for both twins' hospital stays and time away from work. For a stem cell transplant, the recipient still receives high-dose chemotherapy, sometimes with radiation, over a week or two before the new cells are given. This treatment, called conditioning, clears out the diseased marrow and makes room for the donated cells. In a large European registry of twin transplants for aplastic anemia, the new cells failed to take hold more often when conditioning was skipped. The donor twin's stem cells are collected beforehand, usually from the bloodstream and sometimes from the bone marrow.
An organ isograft is the same operation as any living-donor transplant of that organ. Both twins have general anesthesia. One surgical team removes the kidney, or part of the liver, intestine or pancreas, from the donor, and the recipient's team places it and connects it to the recipient's blood vessels. A transplanted kidney often starts making urine soon after blood begins flowing through it, though it sometimes takes a few weeks. A stem cell isograft is not surgery for the recipient. After conditioning, the twin's stem cells are given through an IV, a thin tube placed in a vein, much like a blood transfusion. This usually takes one to five hours. The cells travel to the bone marrow and begin making new blood cells over the following weeks.
Recovery from an organ isograft resembles recovery from any transplant of the same organ, with a hospital stay and a gradual return to normal activity. The main difference comes afterward. Because the twin's organ is not seen as foreign, many recipients need far less anti-rejection medicine, and some stop it after a short initial course. Practice varies: some centers give no ongoing anti-rejection medicine, while a review of twin kidney transplants found that about 60% of recipients still received some. Regular checks of the new organ continue long term, because the original disease can return even when rejection does not. Recovery after a twin stem cell transplant takes longer. Blood counts are checked often while the new cells take hold, and the whole process from conditioning through early recovery can take months, with time in the hospital or staying near it. Even after blood counts recover, the immune system takes about one to two years to rebuild fully. While white blood cell counts are low, infections can become life threatening quickly. Call the transplant team right away for a fever of 100.5 °F (38 °C) or higher, chills, or redness or swelling where an IV line enters the skin.
An isograft removes one major problem, the immune mismatch between donor and recipient, but not the others. The general risks of the surgery, or of the conditioning treatment, remain. For stem cell transplants, high-dose chemotherapy commonly causes nausea, mouth sores, hair loss and fatigue, with a raised risk of bleeding and infection. Later problems can include infertility, cataracts, new cancers and damage to organs such as the heart, lungs, liver or kidneys. For leukemia, a twin transplant carries a specific trade-off. In a large international registry, people with acute myeloid leukemia and chronic myeloid leukemia relapsed more often after a twin transplant than after a transplant from a matched brother or sister. The twin recipients also had fewer deaths from the treatment itself, so their chance of being alive without leukemia three years later was similar. A more recent study of acute myeloid leukemia found the same pattern. A twin is therefore not automatically the best donor, and the choice depends on the type of blood cancer and its stage. For organ isografts, the main threat to the new organ is the disease that damaged the original one. Rejection is not expected, but an autoimmune or other underlying disease can attack the new organ just as it did the old. The clearest example is type 1 diabetes: in early twin pancreas transplants, every recipient needed insulin again within eight weeks because the immune attack on insulin-making cells came back. Autoimmune liver disease has also returned after a twin liver transplant and needed immune-suppressing treatment again. Because twins share inherited risks, a genetic tendency toward kidney disease can affect both the transplanted kidney and the donor's remaining one. The donor twin takes on the risks of living donation, which for an organ means major surgery and life afterward with one kidney or after part of the liver or intestine has been removed.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Isograft, what to expect, or ask the community a question.